Schmulson Wasserman Max, Francisconi Carlos, Olden Kevin, Aguilar Paíz Luis, Bustos-Fernández Luis, Cohen Henry, Passos Maria Carmo, González-Martínez Marina Alejandra, Iade Beatriz, Iantorno Guido, Ledesma Ginatta Carlos, López-Colombo Aurelio, Pérez Cesar Louis, Madrid-Silva Ana María, Quilici Flavio, Quintero Samudio Isaac, Rodríguez Varón Alberto, Suazo Jorge, Valenzuela Jorge, Zolezzi Alberto
Laboratorio de Hígado, Páncreas y Motilidad (HIPAM). Departamento de Medicina Experimental. Facultad de Medicina. Universidad Nacional Autónoma de México (UNAM). Hospital General de México. México.
Gastroenterol Hepatol. 2008 Feb;31(2):59-74. doi: 10.1157/13116072.
The Latin-American Consensus on Chronic Constipation aimed to establish guidelines to improve the identification, diagnosis and treatment of this disorder in the region. Two coordinators and an honorary coordinator established the process and the topics to be discussed, based on a systematic review of the literature published in the previous 10 years, since 1995. Seventeen members participated with the support of their local gastroenterology societies. The members reviewed the different subjects based on the levels of evidence and grades of recommendation; the topics were then discussed in a plenary session. A written report was drafted and the coordinators prepared the final declarations to be submitted to a vote by all the members in October 2006. The consensus concluded that chronic constipation has an estimated prevalence of 5-21% in the region, with a female-to-male ratio of 3:1. Among individuals with constipation, 75% use some type of medication, with more than 50% using home remedies. A diagnosis based on Rome Criteria was recommended and diagnostic testing only in persons older than 50 years or with alarm symptoms. The use of barium enema as an initial investigation was recommended only in countries with a high prevalence of idiopathic megacolon or Chagas' disease. Recommendations on treatment included an increase in dietary fiber of up to 25-30 g/day (grade C). No evidence was found to recommend measures such as exercise, increased water intake, or frequent visits to the toilet. Fiber supplements such as Psyllium received a grade B and pharmacological treatments such as tegaserod and polyethylene glycol, both grade A. There was insufficient evidence to recommend lactulose, but the consensus did not disadvise its use when necessary. Complementary investigations such as colonic transit followed by anorectal manometry and defecography were only recommended to rule out colonic inertia and/or obstructive defecation in patients not responding to treatment. Biofeedback was recommended (grade B) for those with pelvic dyssynergia.
《拉丁美洲慢性便秘共识》旨在制定相关指南,以改善该地区对这种疾病的识别、诊断和治疗。两名协调员和一名荣誉协调员根据对1995年以来过去10年发表的文献进行的系统综述,确定了讨论的流程和主题。17名成员在各自当地胃肠病学学会的支持下参与其中。成员们根据证据水平和推荐等级对不同主题进行了审查;然后在全体会议上对这些主题进行了讨论。起草了一份书面报告,协调员编写了最终声明,于2006年10月提交给所有成员进行表决。该共识得出结论,该地区慢性便秘的估计患病率为5%-21%,女性与男性的比例为3:1。在便秘患者中,75%使用某种类型的药物,超过50%使用家庭疗法。建议根据罗马标准进行诊断,仅对50岁以上或有警示症状的人进行诊断测试。仅在特发性巨结肠或恰加斯病患病率高的国家,建议将钡灌肠作为初步检查手段。治疗建议包括将膳食纤维摄入量增加至每日25-30克(C级)。未发现有证据推荐运动、增加饮水量或频繁上厕所等措施。如车前草等纤维补充剂获得B级推荐,替加色罗和聚乙二醇等药物治疗均为A级推荐。没有足够的证据推荐乳果糖,但该共识并不反对在必要时使用。仅建议进行结肠运输试验,随后进行肛门直肠测压和排粪造影等补充检查,以排除对治疗无反应的患者的结肠无力和/或排便梗阻。对于有盆底协同失调的患者,建议采用生物反馈疗法(B级)。